Tranexamic Acid Update in Trauma

Ricardo J. Ramirez, Philip C. Spinella, Grant V. Bochicchio

Research output: Contribution to journalReview articlepeer-review

58 Scopus citations


Following results from the CRASH-2 trial, tranexamic acid (TXA) gained considerable interest for the treatment of hemorrhage in trauma patients. Although TXA is effective at reducing mortality in patients presenting within 3 hours of injury, optimal dosing, timing of administration, mechanism, and pharmacokinetics require further elucidation. The concept of fibrinolysis shutdown in hemorrhagic trauma patients has prompted discussion of real-time viscoelastic testing and its potential role for appropriate patient selection. The results of ongoing clinical trials will help establish high-quality evidence for optimal incorporation of TXA in mature trauma networks in the United States and abroad.

Original languageEnglish
Pages (from-to)85-99
Number of pages15
JournalCritical Care Clinics
Issue number1
StatePublished - Jan 1 2017


  • Antifibrinolytics
  • Coagulopathy
  • Hemorrhage
  • Surgery
  • Tranexamic acid
  • Trauma


Dive into the research topics of 'Tranexamic Acid Update in Trauma'. Together they form a unique fingerprint.

Cite this